Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alembic Pharmaceuticals Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, ABBAS, ABDULRAHMAN MUSTAFA, and is located within 1 distinct art unit. This indicates a focused prosecution profile with only one active application currently under review by the USPTO.
ABBAS, ABDULRAHMAN MUSTAFA is the busiest examiner for this portfolio, holding the 1 pending office action. Because the company has only 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is entirely centered on this single case. In the Biotechnology & Pharmaceuticals sector, this 1 pending office action represents the company's current primary engagement with the patent office. Practitioners should focus on the specific examination style of ABBAS, ABDULRAHMAN MUSTAFA, as there are no other concurrent cases to provide additional context or alternative prosecution paths within this art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 51.6% | +29.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19003615 | PHARMACEUTICAL COMPOSITION COMPRISING BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION AND PROCESS OF PREPARING THEREOF | ABBAS, ABDULRAHMAN MUSTAFA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19003615 | PHARMACEUTICAL COMPOSITION COMPRISING BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION AND PROCESS OF PREPARING THEREOF | ABBAS, ABDULRAHMAN MUSTAFA | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19003615 | PHARMACEUTICAL COMPOSITION COMPRISING BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION AND PROCESS OF PREPARING THEREOF | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §102§103 | Non-Final OA | — | Pending | Dec 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlembic Pharmaceuticals Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Abdulrahman Mustafa Abbas has the most, with 1 of Alembic Pharmaceuticals Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
